Amgen Inc (AMGN)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 6,717,000 | 7,566,000 | 7,979,000 | 7,917,000 | 6,552,000 | 6,835,000 | 6,576,000 | 5,723,000 | 5,893,000 | 5,609,000 | 5,746,000 | 7,085,000 | 7,264,000 | 7,352,000 | 7,299,000 | 7,675,000 | 7,842,000 | 8,067,000 | 7,958,000 | 8,075,000 |
| Total stockholders’ equity | US$ in thousands | 6,232,000 | 7,656,000 | 6,781,000 | 5,348,000 | 3,661,000 | 3,653,000 | 2,419,000 | 916,000 | 6,700,000 | 8,217,000 | 8,247,000 | 9,334,000 | 9,409,000 | 10,959,000 | 10,659,000 | 9,485,000 | 9,673,000 | 10,927,000 | 10,794,000 | 10,832,000 |
| ROE | 107.78% | 98.82% | 117.67% | 148.04% | 178.97% | 187.11% | 271.85% | 624.78% | 87.96% | 68.26% | 69.67% | 75.91% | 77.20% | 67.09% | 68.48% | 80.92% | 81.07% | 73.83% | 73.73% | 74.55% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $6,717,000K ÷ $6,232,000K
= 107.78%
To analyze AMGEN Inc.'s return on equity (ROE) based on the provided data, we observe a fluctuating trend in ROE across the quarters.
AMGEN's ROE has shown significant variability throughout the periods presented. The ROE ranged from a low of 98.82% in Q3 2023 to a high of 624.78% in Q1 2022. This fluctuation may be indicative of various factors affecting the company's profitability and financial performance during these quarters.
Overall, the ROE trend appears to be trending downwards from Q1 2022 to Q3 2023. The sharp decline from 624.78% in Q1 2022 to 98.82% in Q3 2023 suggests a notable shift in the company's ability to generate profit relative to its shareholders' equity.
Further analysis of the components of ROE, including net income, total equity, and financial leverage, would provide deeper insights into the factors driving these fluctuations in AMGEN's ROE over the quarters. It is important to closely monitor future ROE figures to assess the company's financial performance and efficiency in utilizing its equity to generate returns for shareholders.
Peer comparison
Dec 31, 2023